Finally, in kidney cancer, MARCKS inhibition with MPS peptide synergistically interacted with regorafenib treatment and decreased survival of kidney cancer cells through inactivation of AKT and mTOR (mechanistic target of rapamycin) [34]. Here, MTOR is linked to kidney cancer.